Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Market Expansion Re-Pricing to Hit 23 Meds in April, Opdivo Faces Yet Another Cut in Spillover
A total of 23 drugs (APIs)/38 products will see their prices slashed by market expansion re-pricing in the FY2024 price revision in April, with Ono Pharmaceutical’s I/O agent Opdivo (nivolumab) falling victim to yet another reduction under the so-called “spillover”…
To read the full story
Related Article
REGULATORY
- Japan Urges Priority Supply of Petroleum-Based Materials for Medical Devices
March 31, 2026
- Japan’s New HIV Cases Hit 20-Year Low in 2025
March 30, 2026
- MHLW Launches Genomic Medicine Body GeMJ
March 30, 2026
- TNF Inhibitors, Cancer Drugs Flagged in PMDA Risk Review
March 30, 2026
- Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
March 27, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…